Oritavancin Pharmacokinetics and Bone Penetration in Rabbits-Reference-Cited by-同舟云学术

Oritavancin Pharmacokinetics and Bone Penetration in Rabbits

Published:2015-08-03 Issue:10 Volume:59 Page:6501-6505
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob. Agents Chemother.

Author:

Lehoux Dario^ORCID,Ostiguy Valerie,Cadieux Cordelia,Malouin Mireille,Belanger Odette,Far Adel Rafai,Parr Thomas R.

Abstract

ABSTRACTThe pharmacokinetics and bone concentrations of oritavancin were investigated after a single intravenous dose was administered to rabbits. The pharmacokinetic profile of oritavancin in rabbits showed that it is rapidly distributed to bone tissues, with concentrations remaining stable for up to 168 h, the last measured time point. Based on these findings, further evaluation of oritavancin for the treatment of infections in bone tissues is warranted.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference30 articles.

1. Oritavancin: mechanism of action;Clin Infect Dis,2012

2. Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens;Expert Opin Investig Drugs,2008

3. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials;Antimicrob Agents Chemother,2015

4. Interaction of staphylococci with bone;Int J Med Microbiol,2009

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oritavancin Versus Daptomycin for Osteomyelitis Treatment After Surgical Debridement;Infectious Diseases and Therapy;2024-02-29

2. New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians;Pharmaceuticals;2023-09-15

3. Orthopaedic Implant-Associated Staphylococcal Infections: A Critical Reappraisal of Unmet Clinical Needs Associated with the Implementation of the Best Antibiotic Choice;Antibiotics;2022-03-17

4. Glycopeptide and Lipoglycopeptide Antibiotics;Comprehensive Pharmacology;2022

5. The Use of Long-Acting Lipoglycopeptides for the Treatment of Serious, Off-label Infections: a Review of the Literature;Current Infectious Disease Reports;2021-10-15